1. Home
  2. OTLY vs FBRX Comparison

OTLY vs FBRX Comparison

Compare OTLY & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oatly Group AB

OTLY

Oatly Group AB

HOLD

Current Price

$13.02

Market Cap

320.7M

ML Signal

HOLD

Logo Forte Biosciences Inc.

FBRX

Forte Biosciences Inc.

HOLD

Current Price

$31.28

Market Cap

487.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTLY
FBRX
Founded
1994
N/A
Country
Sweden
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.7M
487.2M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
OTLY
FBRX
Price
$13.02
$31.28
Analyst Decision
Buy
Strong Buy
Analyst Count
5
3
Target Price
$14.50
$67.00
AVG Volume (30 Days)
63.7K
382.1K
Earning Date
04-29-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.30
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$7.91
N/A
Revenue Next Year
$5.50
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.42
$4.91
52 Week High
$18.84
$35.80

Technical Indicators

Market Signals
Indicator
OTLY
FBRX
Relative Strength Index (RSI) 72.39 57.72
Support Level $11.50 $26.67
Resistance Level $18.41 $31.71
Average True Range (ATR) 0.61 3.49
MACD 0.37 0.81
Stochastic Oscillator 96.44 64.25

Price Performance

Historical Comparison
OTLY
FBRX

About OTLY Oatly Group AB

Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.

About FBRX Forte Biosciences Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Share on Social Networks: